Inhibikase Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IKT, updated each market day.
IKT AI Sentiment
AI predicts Inhibikase Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Sector
Exchange
Market Cap
$223,135,154
Cap Tier
Employees
35
Headquarters
WILMINGTON, DE
Listed Since
Dec. 23, 2020
Website
IKT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IKT Volatility
Inhibikase Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
